A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm	Active, not recruiting	Phase 2	2025-08-03		NCT05485948

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
PharmaEssentia	11

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anhui Provincial Hospital	Hefei	China	34
Henan Cancer Hospital	Zhengzhou	China	60
Huashan Hospital affiliated to Fudan University	Shanghai	China	10
Institute of Hematology &Blood Diseases Hospital ,Chinese Academy of medical science & Peking Union Medical College	Tianjin	China	1
Nanfang Hospital affiliated to Southern Medical University	Guangzhou	China	1
Peking Union Medical College Hospital	Beijing	China	112
Ruijin Hospital affiliated to Shanghai Jiaotong University	Shanghai	China	1
Shenzhen Second People's Hospital	Shenzhen	China	6
The First Affiliated Hospital of Chongqing Medical Universit	Chongqing	China	1
The First Affiliated Hospital of Soochow University	Suzhou	China	28
The First Affiliated Hospital Zhejiang University of Medicine	Zhejiang	China	1
The Second Hospital of Tianjin Medical University	Tianjin	China	11
Xiangya Hospital central south university	Changsha	China	12
Zhongnan Hospital Affiliated to Wuhan University	Wuhan	China	3